Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Subscribe To Our Newsletter & Stay Updated
